Evaluation of the Role of -137G/C Single Nucleotide Polymorphism (rs187238) and Gene Expression Levels of the IL-18 in Patients with Coronary Artery Disease.

Objectives Interleukin-18 (IL-18) is a proinflammatory and proatherogenic cytokine, and its genetic variations may contribute to the development of coronary artery disease (CAD). We sought to investigate the role of -137G/C polymorphism and gene expression levels of IL-18 in patients with CAD. Methods The study population included 100 patients with angiographically proven CAD and 100 matched controls. Total RNA and DNA were extracted from leukocytes using appropriate kits. The genotype of -137G/C polymorphism and gene expression level of IL-18 was determined using allele-specific polymerase chain reaction (PCR) and real-time (RT)-PCR assay, respectively. Results The genotypic and allelic distribution of IL-18 -137G/C polymorphism was not significantly different between the two groups (p > 0.050). Moreover, the -137G/C polymorphism did not increase the risk of CAD in dominant and recessive genetic models (p > 0.050). However, subgroup analysis of CAD patients revealed that the IL-18 -137G/C polymorphism was significantly associated with increased risk of CAD in hypertensive patients (odds ratio (OR) = 7.51; 95% confidence interval (CI): 1.24-25.17; p = 0.019) and smokers (OR = 4.90; 95% CI: 1.21-19.70; p = 0.031) but not in the diabetic subpopulation (p = 0.261). The genotype distribution of IL-18 -137G/C genetic polymorphism was significantly different among patients with one, two, and three stenotic vessels (p < 0.050). The gene expression level of IL-18 was significantly higher in the CAD group than the control group (p < 0.001). Moreover, the carriers of CC genotype had significantly lower gene expression levels of IL-18 than carriers of GG genotype (p < 0.050). Conclusions The -137G/C polymorphism of IL-18 may be associated with the CAD risk in hypertensive and smoker subgroup of CAD patients. The -137G/C polymorphism seems to play an important role in determining the severity of CAD. Increased IL-18 gene expression level is a significant risk factor for the development of CAD. The CC genotype of -137G/C polymorphism is associated with lower IL-18 gene expression levels.

[1]  G. Damanhouri,et al.  Assessment of IL‐18 Serum Level and Its Promoter Polymorphisms in the Saudi Coronary Artery Disease (CAD) Patients , 2017, Journal of cellular biochemistry.

[2]  Abdulhakeem Al Rawahi,et al.  Cardiovascular Disease Incidence and Risk Factor Patterns among Omanis with Type 2 Diabetes: A Retrospective Cohort Study. , 2017, Oman medical journal.

[3]  K. Kamali,et al.  Plasma concentration, genetic variation, and gene expression levels of matrix metalloproteinase 9 in Iranian patients with coronary artery disease , 2017, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[4]  Tao Luo,et al.  Genetic polymorphisms -137 (rs187238) and -607 (rs1946518) in the interleukin-18 promoter may not be associated with development of hepatocellular carcinoma , 2016, Scientific Reports.

[5]  S. Humphries,et al.  Influence of cytokine gene polymorphisms on proinflammatory/anti-inflammatory cytokine imbalance in premature coronary artery disease , 2016, Postgraduate Medical Journal.

[6]  M. Runge,et al.  Genetics of coronary artery disease and myocardial infarction. , 2016, World journal of cardiology.

[7]  D. Ramji,et al.  Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets , 2015, Cytokine & growth factor reviews.

[8]  Adhra Al-Mawali,et al.  Non-Communicable Diseases: Shining a Light on Cardiovascular Disease, Oman's Biggest Killer. , 2015, Oman medical journal.

[9]  V. Dhawan,et al.  Role of IL-18 and its signaling in atherosclerosis , 2015 .

[10]  P. Camici,et al.  The role of T and B cells in human atherosclerosis and atherothrombosis , 2015, Clinical and experimental immunology.

[11]  K. Mahajan.  Interleukin-18 and Atherosclerosis: Mediator or Biomarker , 2014 .

[12]  D. Pennington,et al.  Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. , 2014, Biochimica et biophysica acta.

[13]  H. Al-Sabti,et al.  Prevalence Pattern of Risk Factors for Coronary Artery Disease among Patients Presenting for Coronary Artery Bypass Grafting in Oman. , 2014, Oman medical journal.

[14]  G. Lucas,et al.  Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants , 2014, The application of clinical genetics.

[15]  C. Dinarello,et al.  Interleukin-18 and IL-18 Binding Protein , 2013, Front. Immunol..

[16]  Wenwei Liu,et al.  Plasma Levels of Interleukin 18, Interleukin 10, and Matrix Metalloproteinase-9 and -137G/C Polymorphism of Interleukin 18 Are Associated with Incidence of In-stent Restenosis After Percutaneous Coronary Intervention , 2013, Inflammation.

[17]  B. Machaliński,et al.  The impact of IL18 gene polymorphisms on mRNA levels and interleukin-18 release by peripheral blood mononuclear cells. , 2012, Postepy higieny i medycyny doswiadczalnej.

[18]  M. Woodward,et al.  Interleukin 18 and coronary heart disease: Prospective study and systematic review , 2011, Atherosclerosis.

[19]  Z. M. I. Dezayee.  Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus , 2011, International journal of applied & basic medical research.

[20]  D. Petrovič,et al.  Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in Slovenia , 2011, Balkan journal of medical genetics : BJMG.

[21]  T. Lehtimäki,et al.  Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. , 2009, European heart journal.

[22]  Casey S. Greene,et al.  Failure to Replicate a Genetic Association May Provide Important Clues About Genetic Architecture , 2009, PloS one.

[23]  H. Sillesen,et al.  Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[24]  Wenwei Liu,et al.  Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. , 2009, Angiology.

[25]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[26]  E. Lambert,et al.  The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. , 2007, European journal of endocrinology.

[27]  P. Sehgal,et al.  Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter. , 2006, Biochimica et biophysica acta.

[28]  V. Giedraitis,et al.  Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation , 2001, Journal of Neuroimmunology.

[29]  H. Arnesen,et al.  Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an Observational Study , 2011, Cardiovascular diabetology.

[30]  A. Ghaderi,et al.  Interleukin-18 Gene Polymorphism in Patients with and without Atherosclerotic Coronary Artery Disease , 2009 .